Enveda Biosciences was last valued at $650M (post-money). It comes from the $130M Series C of Nov 2024. The company is private, so there is no listed share price.
1 valuation. The latest, $650M post-money, was set by the Series C in Nov 2024.
A private valuation is the price agreed in one transaction. The Enveda Biosciences valuation of $650M is a post-money figure from the Series C dated 29 Nov 2024 — the whole company measured after the $130M raised in that round was already inside it. Subtract the round and the pre-money view of the same deal is $520M .
The valuation holds until the next priced round or secondary sale. A private company founded in 2018 with roughly 120 people has no daily price and no order book between rounds.
The last valuation is $650M.
Lead investors for each round are in the funding timeline.
The closest ai drug discovery peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Enveda Biosciences is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
